Helicobacter pylori and Campylobacter spp. are leading causes of gastrointestinal illness worldwide. Existing solutions are limited, and there's a need for broad-spectrum protection. acib offers a dual-protection vaccine platform using H. pylori to deliver Campylobacter antigens, potentially reducing development time and costs for future multi-pathogen vaccines.
Background
A Nobel prize was awarded in 2005 for work on Helicobacter pylori and it’s role in causing ulcers. H. pylori is a gram-negative bacterium able to move using its flagella. It’s not only able to survive, but also to thrive in the acidic environment of our stomach, creating a protective niche for itself. H. pylori is not only a causative agent for peptic ulcers, but long-term exposure is also a risk for stomach cancer. Campylobacter spp. is one of the main causes of foodborne disease in developed countries and the number one cause of bacterial gastroenteritis in Europe with approximately a quarter million cases each year and a leading cause of bacterial diarrhoeal illness worldwide. As of recently, both have been extensively studied and also genetic tools for manipulation have been developed.
Technology
Imagine you could simultaneously be protected from H. pylori and Campylobacter spp. Sabine Kienesberger has worked for years both on H. pylori and Campylobacter spp., developing a unique understanding of their physiology and pathogenicity. She is now focusing on a project expressing universal Campylobacter antigens on the surface of H. pylori to be presented alongside their own antigens. Upon oral ingestion this vaccine hits two birds with one stone, contributing to a more comprehensive gastrointestinal health in humans.
Offer
We are looking for partners in developing this next-generation vaccination strategy, which can later be extended to other gastro-intestinal pathogens e.g. Shigella, but also viral agents such as Norovirus, where surface antigens of several strains could be presented in parallel to yield a single, universal vaccine. acib would exclusively and fully transfer all intellectual property developed in this project to you as our company partner/investor.
Contact us to find out about the future of gastrointestinal health solutions!
Experts:
Dr. Sabine Kienesberger-FeistDevelopment status:
Technology Readiness Level 2 (Technology concept formulated)IPR:
To be generated for project partnerKeywords:
Vaccine Platform, Gastrointestinal Health, Peptic Ulcers, Stomach Cancers, Gastroenteritis, Oral Vaccination, Dual Protection, Unmet medical needs
